Discounted Cash Flow (DCF) Analysis Levered
TG Therapeutics, Inc. (TGTX)
$26.77
+0.92 (+3.56%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 0.15 | 0.15 | 0.15 | 6.69 | 2.78 | 61.86 | 1,373.98 | 30,518.06 | 677,850.90 | 15,056,063.02 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -128.92 | -132.81 | -214.51 | -295.63 | -176.17 | -40,092 | -890,502.03 | -19,779,356.48 | -439,328,525.28 | -9,758,131,076.51 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.09 | -0.13 | -0.36 | -0.40 | -2.69 | -59.73 | -1,326.77 | -29,469.62 | -654,563.46 | -14,538,814.84 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -129.01 | -132.94 | -214.86 | -296.03 | -178.86 | -40,151.73 | -891,828.80 | -19,808,826.10 | -439,983,088.74 | -9,772,669,891.35 |
Weighted Average Cost Of Capital
| Share price | $ 26.77 |
|---|---|
| Beta | 2.081 |
| Diluted Shares Outstanding | 135.41 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 85.46% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 13.526 |
| Total Debt | 11.93 |
| Total Equity | 3,624.96 |
| Total Capital | 3,636.88 |
| Debt Weighting | 0.33 |
| Equity Weighting | 99.67 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 0.15 | 0.15 | 0.15 | 6.69 | 2.78 | 61.86 | 1,373.98 | 30,518.06 | 677,850.90 | 15,056,063.02 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -128.92 | -132.81 | -214.51 | -295.63 | -176.17 | -40,092 | -890,502.03 | -19,779,356.48 | -439,328,525.28 | -9,758,131,076.51 |
| Capital Expenditure | -0.09 | -0.13 | -0.36 | -0.40 | -2.69 | -59.73 | -1,326.77 | -29,469.62 | -654,563.46 | -14,538,814.84 |
| Free Cash Flow | -129.01 | -132.94 | -214.86 | -296.03 | -178.86 | -40,151.73 | -891,828.80 | -19,808,826.10 | -439,983,088.74 | -9,772,669,891.35 |
| WACC | ||||||||||
| PV LFCF | -35,295.12 | -689,131.86 | -13,455,194.78 | -262,710,632.88 | -5,129,385,173.78 | |||||
| SUM PV LFCF | -5,406,275,428.42 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 13.76 |
| Free cash flow (t + 1) | -9,968,123,289.17 |
| Terminal Value | -84,762,953,139.23 |
| Present Value of Terminal Value | -44,489,565,282.80 |
Intrinsic Value
| Enterprise Value | -49,895,840,711.22 |
|---|---|
| Net Debt | -90.38 |
| Equity Value | -49,895,840,620.84 |
| Shares Outstanding | 135.41 |
| Equity Value Per Share | -368,476,309.56 |